TITAN PHARMACEUTICALS, INC. WARRANT TO PURCHASE SHARES OF STOCKWarrant Agreement • March 26th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 26th, 2018 Company Industry JurisdictionTHIS CERTIFIES THAT, for value received, _______________ and its assignees (“Warrant Holder”) are entitled to subscribe for and purchase _________ fully paid and nonassessable shares (the “Shares”) of common stock, $.001 par value (the “Common Stock of TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), at the price per share equal to $1.20 ( “Warrant Price”), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, (a) the term “Shares” shall mean the Common Stock and any stock into or for which such Common Stock may hereafter be converted or exchanged; (b) the term “Date of Grant” shall mean March 21, 2018, and (c) the term “Other Warrants” shall mean any warrant issued upon transfer or partial exercise of or in lieu of this Warrant. The term “Warrant” as used herein shall be deemed to include Other Warrants unless the context clearly requires otherwise. The Warrant Price and the number of Shares issuable upon exercise of thi
ContractWarrant Agreement • May 13th, 2015 • Nivalis Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 13th, 2015 Company Industry JurisdictionTHIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.
ContractWarrant Agreement • May 13th, 2015 • Nivalis Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 13th, 2015 Company Industry JurisdictionTHIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.
ContractWarrant Agreement • February 13th, 2015 • Nivalis Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 13th, 2015 Company Industry JurisdictionTHIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.
ContractWarrant Agreement • February 13th, 2015 • Nivalis Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 13th, 2015 Company Industry JurisdictionTHIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.